Advertisement

Bubble-Assisted Ultrasound: Application in Immunotherapy and Vaccination

  • Jean-Michel EscoffreEmail author
  • Roel Deckers
  • Clemens BosEmail author
  • Chrit Moonen
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 880)

Abstract

Bubble-assisted ultrasound is a versatile technology with great potential in immunotherapy and vaccination. This technology involves the exposure of immune cells (i.e., dendritic cells, lymphocytes) in-vitro or diseased tissues (i.e., brain, tumor) in-vivo to ultrasound treatment with gas bubbles. Bubble destruction leads to physical forces that induce the direct delivery of weakly permeant immuno-stimulatory molecules either into the cytoplasm of immune cells, or through the endothelial barrier of diseased tissues. Hence, therapeutic antibodies (i.e., antibody-based immunotherapy) and cytokine-encoding nucleic acids (i.e., cytokine gene therapy) can be successfully delivered into diseased tissues, thus improving immune responses. In addition, protein antigens, as well as antigen-encoding nucleic acids (pDNA, mRNA), can be delivered into dendritic cells (i.e., dendritic cell-based vaccines), thus leading to a long-lasting prophylactic or therapeutic immunization. This chapter focuses on the state-of-the-art of bubble-assisted ultrasound in the field of immunotherapy and vaccination.

Keywords

Ultrasound Bubble Immunotherapy Vaccination 

References

  1. Abbas AK, Lichtman AH (2006) Basic immunology: functions and disorders of the immune system. Saunders Edition, PhiladelphiaGoogle Scholar
  2. Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM (2004) Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22:2891–2900CrossRefPubMedGoogle Scholar
  3. Andre FE (2003) Vaccinology: past achievements, present roadblocks and future promises. Vaccine 21:593–595CrossRefPubMedGoogle Scholar
  4. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32CrossRefGoogle Scholar
  5. Aryal M, Arvanitis CD, Alexander PM, Mcdannold N (2014) Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev 72C:94–109CrossRefGoogle Scholar
  6. Aurisicchio L, Ciliberto G (2012) Genetic cancer vaccines: current status and perspectives. Expert Opin Biol Ther 12:1043–1058CrossRefPubMedGoogle Scholar
  7. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer’s disease. Peptides 23:2223–2226CrossRefPubMedGoogle Scholar
  8. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916–919CrossRefPubMedGoogle Scholar
  9. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977CrossRefPubMedGoogle Scholar
  10. Black D, Brockway-Lunardi L (2013) The melanoma research alliance: the power of patient advocacy to accelerate research and novel therapies. Cancer Immunol Res 1:357–361CrossRefPubMedGoogle Scholar
  11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMedGoogle Scholar
  12. Bose P, Brockton NT, Dort JC (2013) Head and neck cancer: from anatomy to biology. Int J Cancer 133:2013–2023CrossRefPubMedGoogle Scholar
  13. Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50:4478–4484PubMedGoogle Scholar
  14. Burgess A, Hynynen K (2014) Drug delivery across the blood-brain barrier using focused ultrasound. Expert Opin Drug Deliv 11:711–721PubMedCentralCrossRefPubMedGoogle Scholar
  15. Chacko AM, Li C, Pryma DA, Brem S, Coukos G, Muzykantov V (2013) Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv 10:907–926PubMedCentralCrossRefPubMedGoogle Scholar
  16. Chang EL, Lo S (2003) Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 8:398–410CrossRefPubMedGoogle Scholar
  17. Chi CH, Wang YS, Lai YS, Chi KH (2003) Anti-tumor effect of in vivo IL-2 and GM-CSF electrogene therapy in murine hepatoma model. Anticancer Res 23:315–321PubMedGoogle Scholar
  18. Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ (2012) Dendritic cell-based vaccines: barriers and opportunities. Future Oncol 8:1273–1299PubMedCentralCrossRefPubMedGoogle Scholar
  19. Daud AI, Deconti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896–5903PubMedCentralCrossRefPubMedGoogle Scholar
  20. De Temmerman ML, Dewitte H, Vandenbroucke RE, Lucas B, Libert C, Demeester J, De Smedt SC, Lentacker I, Rejman J (2011) mRNA-Lipoplex loaded microbubble contrast agents for ultrasound-assisted transfection of dendritic cells. Biomaterials 32:9128–9135CrossRefPubMedGoogle Scholar
  21. Demattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 98:8850–8855PubMedCentralCrossRefPubMedGoogle Scholar
  22. Doinikov AA, Bouakaz A (2010) Acoustic microstreaming around a gas bubble. J Acoust Soc Am 127:703–709CrossRefPubMedGoogle Scholar
  23. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK (2011) The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8:344–356PubMedCentralPubMedGoogle Scholar
  24. Escoffre JM, Kaddur K, Rols MP, Bouakaz A (2010a) In vitro gene transfer by electrosonoporation. Ultrasound Med Biol 36:1746–1755CrossRefPubMedGoogle Scholar
  25. Escoffre JM, Teissie J, Rols MP (2010b) Gene transfer: how can the biological barriers be overcome? J Membr Biol 236:61–74CrossRefPubMedGoogle Scholar
  26. Escoffre JM, Novell A, Serriere S, Lecomte T, Bouakaz A (2013a) Irinotecan delivery by microbubble-assisted ultrasound: in vitro validation and a pilot preclinical study. Mol Pharm 10:2667–2675CrossRefPubMedGoogle Scholar
  27. Escoffre JM, Zeghimi A, Novell A, Bouakaz A (2013b) In-vivo gene delivery by sonoporation: recent progress and prospects. Curr Gene Ther 13:2–14CrossRefPubMedGoogle Scholar
  28. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRefPubMedGoogle Scholar
  29. Foged C (2011) Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv 2:1057–1077CrossRefPubMedGoogle Scholar
  30. Frenkel V (2008) Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev 60:1193–1208PubMedCentralCrossRefPubMedGoogle Scholar
  31. Gollob JA, Mier JW, Veenstra K, Mcdermott DF, Clancy D, Clancy M, Atkins MB (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6:1678–1692PubMedGoogle Scholar
  32. Hauff P, Seemann S, Reszka R, Schultze-Mosgau M, Reinhardt M, Buzasi T, Plath T, Rosewicz S, Schirner M (2005) Evaluation of gas-filled microparticles and sonoporation as gene delivery system: feasibility study in rodent tumor models. Radiology 236:572–578CrossRefPubMedGoogle Scholar
  33. Heath CH, Sorace A, Knowles J, Rosenthal E, Hoyt K (2012) Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo. Otolaryngol Head Neck Surg 146:938–945PubMedCentralCrossRefPubMedGoogle Scholar
  34. Heller LC, Heller R (2010) Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 10:312–317CrossRefPubMedGoogle Scholar
  35. Horton JK, Halle J, Ferraro M, Carey L, Moore DT, Ollila D, Sartor CI (2010) Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys 76:998–1004CrossRefPubMedGoogle Scholar
  36. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:39–51CrossRefPubMedGoogle Scholar
  37. Ittner LM, Gotz J (2011) Amyloid-beta and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 12:65–72CrossRefPubMedGoogle Scholar
  38. Iwanaga K, Tominaga K, Yamamoto K, Habu M, Maeda H, Akifusa S, Tsujisawa T, Okinaga T, Fukuda J, Nishihara T (2007) Local delivery system of cytotoxic agents to tumors by focused sonoporation. Cancer Gene Ther 14:354–363CrossRefPubMedGoogle Scholar
  39. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, Finher Study I (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820CrossRefPubMedGoogle Scholar
  40. Jordao JF, Ayala-Grosso CA, Markham K, Huang Y, Chopra R, Mclaurin J, Hynynen K, Aubert I (2010) Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer’s disease. PLoS One 5:e10549PubMedCentralCrossRefPubMedGoogle Scholar
  41. Kinoshita M, Mcdannold N, Jolesz FA, Hynynen K (2006) Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A 103:11719–11723PubMedCentralCrossRefPubMedGoogle Scholar
  42. Kotopoulis S, Dimcevski G, Gilja OH, Hoem D, Postema M (2013) Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study. Med Phys 40:072902CrossRefPubMedGoogle Scholar
  43. Lemmon JC, Mcfarland RJ, Rybicka JM, Balce DR, Mckeown KR, Krohn RM, Matsunaga TO, Yates RM (2011) In vitro and in vivo transfection of primary phagocytes via microbubble-mediated intraphagosomal sonoporation. J Immunol Methods 371:152–158CrossRefPubMedGoogle Scholar
  44. Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278–5286CrossRefPubMedGoogle Scholar
  45. Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ (2012) Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol 8:465–469PubMedGoogle Scholar
  46. Logan RM (2009) Advances in understanding of toxicities of treatment for head and neck cancer. Oral Oncol 45:844–848CrossRefPubMedGoogle Scholar
  47. Lucas ML, Heller L, Coppola D, Heller R (2002) IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5:668–675CrossRefPubMedGoogle Scholar
  48. Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P (2007) Intratumoral injection of IL-12 plasmid DNA–results of a phase I/IB clinical trial. Cancer Gene Ther 14:717–723CrossRefPubMedGoogle Scholar
  49. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592CrossRefPubMedGoogle Scholar
  50. Oda Y, Suzuki R, Otake S, Nishiie N, Hirata K, Koshima R, Nomura T, Utoguchi N, Kudo N, Tachibana K, Maruyama K (2012) Prophylactic immunization with Bubble liposomes and ultrasound-treated dendritic cells provided a four-fold decrease in the frequency of melanoma lung metastasis. J Control Release 160:362–366CrossRefPubMedGoogle Scholar
  51. Ohl CD, Wolfrum B (2003) Detachment and sonoporation of adherent HeLa-cells by shock wave-induced cavitation. Biochim Biophys Acta 1624:131–138CrossRefPubMedGoogle Scholar
  52. Ohl CD, Arora M, Ikink R, De Jong N, Versluis M, Delius M, Lohse D (2006) Sonoporation from jetting cavitation bubbles. Biophys J 91:4285–4295PubMedCentralCrossRefPubMedGoogle Scholar
  53. Opar A (2008) Mixed results for disease-modification strategies for Alzheimer’s disease. Nat Rev Drug Discov 7:717–718CrossRefPubMedGoogle Scholar
  54. Park EJ, Zhang YZ, Vykhodtseva N, Mcdannold N (2012) Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release 163:277–284PubMedCentralCrossRefPubMedGoogle Scholar
  55. Price KA, Cohen EE (2012) Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13:35–46CrossRefPubMedGoogle Scholar
  56. Raymond SB, Treat LH, Dewey JD, Mcdannold NJ, Hynynen K, Bacskai BJ (2008) Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer’s disease mouse models. PLoS One 3:e2175PubMedCentralCrossRefPubMedGoogle Scholar
  57. Ren H, Boulikas T, Lundstrom K, Soling A, Warnke PC, Rainov NG (2003) Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene–a phase I/II clinical protocol. J Neurooncol 64:147–154PubMedGoogle Scholar
  58. Sakakima Y, Hayashi S, Yagi Y, Hayakawa A, Tachibana K, Nakao A (2005) Gene therapy for hepatocellular carcinoma using sonoporation enhanced by contrast agents. Cancer Gene Ther 12:884–889CrossRefPubMedGoogle Scholar
  59. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S (2014) Melanoma immunotherapy. Cancer Biol Ther 15:665–674PubMedCentralCrossRefPubMedGoogle Scholar
  60. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287CrossRefPubMedGoogle Scholar
  61. Suzuki R, Namai E, Oda Y, Nishiie N, Otake S, Koshima R, Hirata K, Taira Y, Utoguchi N, Negishi Y, Nakagawa S, Maruyama K (2010) Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release 142:245–250CrossRefPubMedGoogle Scholar
  62. Taylor SL, Rahim AA, Bush NL, Bamber JC, Porter CD (2007) Targeted retroviral gene delivery using ultrasound. J Gene Med 9:77–87CrossRefPubMedGoogle Scholar
  63. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, Stewart GR, Shafer LL (2009) Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A 106:4501–4506PubMedCentralCrossRefPubMedGoogle Scholar
  64. Un K, Kawakami S, Suzuki R, Maruyama K, Yamashita F, Hashida M (2010) Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials 31:7813–7826CrossRefPubMedGoogle Scholar
  65. Un K, Kawakami S, Suzuki R, Maruyama K, Yamashita F, Hashida M (2011) Suppression of melanoma growth and metastasis by DNA vaccination using an ultrasound-responsive and mannose-modified gene carrier. Mol Pharm 8:543–554CrossRefPubMedGoogle Scholar
  66. Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15:555–569PubMedCentralPubMedGoogle Scholar
  67. Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC (2013) The blood-brain barrier: an engineering perspective. Front Neuroeng 6:7PubMedCentralCrossRefPubMedGoogle Scholar
  68. Zolochevska O, Xia X, Williams BJ, Ramsay A, Li S, Figueiredo ML (2011) Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum Gene Ther 22:1537–1550CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Imaging DivisionUniversity Medical Center UtrechtUtrechtThe Netherlands

Personalised recommendations